Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of relevance. This is page number 13.
Order by Relevance | Date
Total 36353 results found since Jan 2013.
Decreased FOXP3+ and GARP+ Tregs to neoadjuvant chemotherapy associated with favorable prognosis in advanced gastric cancer
Source: OncoTargets and Therapy - June 14, 2016 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients
Mammography and ultrasound are the gold standard imaging techniques for preoperative assessment and for monitoring the efficacy of neoadjuvant chemotherapy in breast cancer. Maximum accuracy in predicting path...
Source: BMC Cancer - July 13, 2016 Category: Cancer & Oncology Authors: Roland Gregor Stein, Daniel Wollschläger, Rolf Kreienberg, Wolfgang Janni, Manfred Wischnewsky, Joachim Diessner, Tanja Stüber, Catharina Bartmann, Mathias Krockenberger, Jörg Wischhusen, Achim Wöckel, Maria Blettner and Lukas Schwentner Source Type: research
Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection ‐site sarcoma: results in 21 cats
This study assesses the outcome of two combined treatment strategies for the treatment of feline injection‐site sarcoma (FISS). Twenty‐one cats with primary or recurrent FISS received 3 cycles of neoadjuvant chemotherapy with epirubicin (25 mg m−2), then an anatomical resection of the entire muscle compartment containing the tumour was performed based on the findings of co‐axial imaging. Cats then received a further 3 cycles of adjuvant chemotherapy. Follow‐up was performed by telephone contact with a median follow‐up time of 1072 days. Three cats (14%) developed local tumour recurrence at days 264, 6...
Source: Veterinary and Comparative Oncology - February 6, 2014 Category: Veterinary Research Authors: J. Bray, G. Polton Tags: Original Article Source Type: research
Role of Magnetic Resonance Imaging in Primary Rectal Cancer —Standard Protocol and Beyond
New-generation magnetic resonance imaging (MRI) scanners with optimal phased-array body coils have contributed to obtainment of high-resolution T2-weighted turbo spin echo images in which visualization of anatomical details such as the mesorectal fascia and the bowel wall layers is feasible. Preoperative, locoregional staging of rectal cancer with MRI, considered standard of care nowadays, relies on these images for stratification of high-risk patients for local recurrence, patients most likely to benefit from neoadjuvant therapy, as well as patients who exhibit imaging features indicative of a high risk of metastatic disease.
Source: Seminars in Ultrasound CT and MRI - February 14, 2016 Category: Radiology Authors: Sofia Gourtsoyianni, Nickolas Papanikolaou Source Type: research
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
Source: OncoTargets and Therapy - July 20, 2016 Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The Effects of Preoperative Radiotherapy on Head and Neck Free Flap Anastomosis Success
The long-term survival benefit of neoadjuvant radiotherapy for oropharyngeal tumors is controversially discussed in the literature. To bring more light into this important debate, we evaluated our cases.
Source: Journal of Oral and Maxillofacial Surgery - May 24, 2016 Category: ENT & OMF Authors: Claudio Rostetter, Irina M. Kuster, Jan S. Schenkel, Martin Lanzer, Thomas Gander, Astrid L. Kruse Tags: Surgical oncology and reconstruction Source Type: research
Role of Magnetic Resonance Imaging in Primary Rectal Cancer —Standard Protocol and Beyond
New-generation magnetic resonance imaging (MRI) scanners with optimal phased-array body coils have contributed to obtainment of high-resolution T2-weighted turbo spin echo images in which visualization of anatomical details such as the mesorectal fascia and the bowel wall layers is feasible. Preoperative, locoregional staging of rectal cancer with MRI, considered standard of care nowadays, relies on these images for stratification of high-risk patients for local recurrence, patients most likely to benefit from neoadjuvant therapy, as well as patients who exhibit imaging features indicative of a high risk of metastatic disease.
Source: Seminars in Ultrasound CT and MRI - February 14, 2016 Category: Radiology Authors: Sofia Gourtsoyianni, Nickolas Papanikolaou Source Type: research
Chemotherapy Agents With Known Cardiovascular Side Effects and Their Anesthetic Implications
Many cancer patients undergo surgical resection of their primary cancers for curative intent or may need surgery as part of palliative treatment of an advanced-stage cancer. Chemotherapy often is administered preoperatively (neoadjuvant chemotherapy) to facilitate adequate resection of the primary tumor. Alternatively, cancer patients may require emergency procedures, often due to complications related to their progressing disease and ongoing pharmacotherapy, or surgeries unrelated to their neoplasm.
Source: Journal of Cardiothoracic and Vascular Anesthesia - March 3, 2016 Category: Anesthesiology Authors: Adriana D. Oprea, Raymond R. Russell, Kerry S. Russell, Maysa Abu-Khalaf Tags: Review ArticleGiovanni Landoni, MDSection Editors? > Source Type: research
Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage III C and IV epithelial ovarian cancer
Source: ClinicoEconomics and Outcomes Research - August 1, 2016 Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
The effect of neoadjuvant chemotherapy and chemoradiotherapy on exercise capacity and outcome following upper gastrointestinal cancer surgery: an observational cohort study
In 2014 approximately 21,200 patients were diagnosed with oesophageal and gastric cancer in England and Wales, of whom 37 % underwent planned curative treatments. Potentially curative surgical resection is ass...
Source: BMC Cancer - September 2, 2016 Category: Cancer & Oncology Authors: M. A. West, L. Loughney, G. Ambler, B. D. Dimitrov, J. J. Kelly, M. G. Mythen, R. Sturgess, P. M. A. Calverley, A. Kendrick, M. P. W. Grocott and S. Jack Source Type: research
Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer
(European Society for Medical Oncology) Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.
Source: EurekAlert! - Medicine and Health - October 7, 2016 Category: Global & Universal Source Type: news
Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties
The management of locally advanced breast cancer (LABC) remains a major clinical issue, despite progress achieved in diagnosis and therapy. Preoperative or neoadjuvant therapy has gained interest since breast cancer has been regarded as a systemic disease. Comparing adjuvant versus neoadjuvant treatment, the neoadjuvant approach offers the advantage of downstaging the disease and testing the efficacy of therapy administered to patients. A large number of clinical trials have attempted to define the optimal neoadjuvant treatment, but little attention has been paid to the sequence of chemotherapy.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - December 13, 2016 Category: OBGYN Authors: Mick Van de Wiel, Yanina Dockx, Tim Van den Wyngaert, Sigrid Stroobants, Wiebren A.A. Tjalma, Manon T. Huizing Tags: Review article Source Type: research
Comparison of survival outcome of patients with primary peritoneal and fallopian tube carcinoma treated with neoadjuvant chemotherapy versus primary debulking surgery.
This study examines the overall survival of primary peritoneal cancer (PPC), in those patients who had primary debulking surgery (PDS) followed by six cycles of chemotherapy versus those who had neoadjuvant chemotherapy (NACT). This was a prospective observational study performed at Oxford Gynaecological Cancer Centre, over a 5-year period. Eighty-seven patients were clinically suspected of having PPC. Histology confirmed that 64 of these were PPC, with the balance being tubal in origin. PDS was performed in 31 cases. Although NACT was planned in 56 patients, 4 patients didn't receive NACT and therefore excluded from the s...
Source: Journal of Obstetrics and Gynaecology - December 16, 2016 Category: OBGYN Tags: J Obstet Gynaecol Source Type: research
Fatigue during and after breast cancer therapy – A prospective study
Chronic fatigue (CF) in breast cancer (BC) survivors is multifactorial and may be caused by immune activation triggered by BC or its treatment. In the NeoAva study, BC patients received neoadjuvant chemotherapy (FEC100 →taxane) +/-bevacizumab, a monoclonal antibody with fatigue as a potential side effect.
Source: Journal of Pain and Symptom Management - December 29, 2016 Category: Palliative Care Authors: Kristin V. Reinertsen, Olav Engebraaten, Jon H. Loge, Milada Cvancarova, Bj ørn Naume, Erik Wist, Hege Edvardsen, Elisabeth Wille, Trine Bjøro, Cecilie E. Kiserud Source Type: research
CRLX101, a Nanoparticle-Drug Conȷugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1{alpha}
In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therapeutic responses as compared with standard chemotherapy. CRLX101 was evaluated as a radiosensitizer in colorectal cancer cell lines and murine xenograft models. CRLX101 was as potent as CPT in vitro in its ability to radiosensitize cancer cells. Evaluations in vivo demonstrated that the addition of CRLX101 to standard chemoradiotherapy significantly increased therapeutic efficacy by inhibiting DNA repair and HIF1α pathway activation in tumor cells. Notably, CRLX101 ...
Source: Cancer Research - January 1, 2017 Category: Cancer & Oncology Authors: Xi Tian, Minh Nguyen, Henry P. Foote, Joseph M. Caster, Kyle C. Roche, Christian G. Peters, Pauline Wu, Lata Jayaraman, Edward G. Garmey, Joel E. Tepper, Scott Eliasof, Andrew Z. Wang Tags: Molecular and Cellular Pathobiology Source Type: research
